{
    "2021-10-29": [
        [
            {
                "time": "2021-10-29",
                "original_text": "国产新冠疫苗迎“收获期”，龙头企业三季度业绩暴涨",
                "features": {
                    "keywords": [
                        "新冠疫苗",
                        "收获期",
                        "龙头企业",
                        "三季度",
                        "业绩暴涨"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-10-29",
                "original_text": "智飞生物（300122）：主营增长依然强势 新冠海外销售期待突破",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "主营增长",
                        "新冠",
                        "海外销售",
                        "突破"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-10-29",
                "original_text": "国盛证券维持智飞生物买入评级：非新冠产品业绩贡献超预期，坚定看好公司未来发展",
                "features": {
                    "keywords": [
                        "国盛证券",
                        "智飞生物",
                        "买入评级",
                        "非新冠产品",
                        "业绩贡献",
                        "超预期"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-10-29",
                "original_text": "华西证券：给予智飞生物买入评级",
                "features": {
                    "keywords": [
                        "华西证券",
                        "智飞生物",
                        "买入评级"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-10-29",
                "original_text": "智飞生物新冠疫苗等自研产品放量 助推净利润同比大增239.05%",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "新冠疫苗",
                        "自研产品",
                        "放量",
                        "净利润",
                        "同比大增"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-10-29",
                "original_text": "智飞生物前三季度净利润大增239% 新冠疫苗成为增长主力",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "前三季度",
                        "净利润",
                        "大增",
                        "新冠疫苗",
                        "增长主力"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-10-29",
                "original_text": "操盘必读｜张坤加仓伊利减持泸州老窖，智飞生物三季度净增2倍！标普、纳指创新高",
                "features": {
                    "keywords": [
                        "张坤",
                        "加仓",
                        "伊利",
                        "减持",
                        "泸州老窖",
                        "智飞生物",
                        "三季度",
                        "净增",
                        "标普",
                        "纳指",
                        "创新高"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药",
                        "消费",
                        "科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-10-29",
                "original_text": "“中国民营疫苗第一股”重庆智飞生物前三个季度赚84亿元额增239% 股东数减筹码集中",
                "features": {
                    "keywords": [
                        "中国民营疫苗第一股",
                        "重庆智飞生物",
                        "前三个季度",
                        "84亿元",
                        "额增",
                        "股东数减",
                        "筹码集中"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}